ArticleTranslational cancer research2026
Efficacy and safety of antibody-drug conjugates in advanced small cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antibody-drug conjugates (ADCs) are being evaluated in advanced small cell lung cancer (SCLC), but the available trials include different targets, constructs, doses, and treatment settings. We aimed to determine the overall range of reported activity and safety while clarifying whether the evidence supports a clinically uniform ADC class effect. Methods: PubMed/MEDLINE, Embase, Web of Science, the Cochrane Central Register of Controlled Trials (CENTRAL), clinical-trial registries, and major oncology conference proceedings were searched from inception through July 31, 2026. Eligibility was restricted to reports with sufficient methodological and outcome information available in English; study country, recruitment region, investigator nationality, and participant ethnicity were not exclusion criteria. Prospective phase I-III studies of ADC monotherapy in adults with advanced, extensive-stage, relapsed, or refractory SCLC were eligible; no comparator was required, and only the ADC arm of comparative trials contributed to the single-arm synthesis. Outcomes were objective response rate (ORR), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and clinically important safety events. Randomized trials were assessed using the Cochrane risk-of-bias tool and non-comparative studies using the Methodological Index for Non-Randomized Studies (MINORS). Random-effects models were used, with subgroup and sensitivity analyses. Results: Eighteen prospective studies comprising 20 analytic cohorts and 2,246 patients were included: 12 phase I/Ib/I-II studies, three phase II studies, and three phase III studies. The pooled ORR was 34.38% [95% confidence interval (CI): 24.96-44.43%; I Conclusions: ADC-based therapy shows antitumor activity in advanced SCLC, but substantial clinical and pharmacological heterogeneity limits the interpretation of pooled single-arm estimates. Agent-specific randomized trials with standardized efficacy, safety, and biomarker reporting are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.